Added to YB: 2024-07-12
Pitch date: 2024-07-10
HLVX [bullish]
HilleVax, Inc.
+24.4%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States.
Market Cap
$102.5M
Pitch Price
$1.68
Price Target
2.56 (+22%)
Dividend
N/A
EV/EBITDA
0.70
P/E
-1.45
EV/Sales
N/A
Sector
Biotechnology
Category
turnaround
Show full summary:
HilleVax: Failed Vaccine Trial, Pre-SA, Trading Below Cash
HLVX: Failed HIL-214 trial; stock below cash. $85M mkt cap. Q1 cash $252M, est. Q2 $224M. Potential $50M burn. Exploring HIL-216 in adults. Risky vs. others in wind-down. 14% owned by Takeda. ATM raised $15M+ in Q1/Q2. Catalysts: strategic alternatives, conclusion. PT $2.56.
Read full article (2 min)